Latest News
News Functions
Additional Functions
5 September 2014
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia
24 July 2014
Keryx Biopharmaceuticals, Inc.
Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology
Keryx Biopharmaceuticals, Inc.
Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology
18 June 2014
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate
8 May 2014
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2014 Financial Results
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2014 Financial Results
15 April 2014
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and Legal
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and Legal
9 April 2014
Keryx Biopharmaceuticals, Inc.
GlobeNewswire Press Release: Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc.
GlobeNewswire Press Release: Keryx Biopharmaceuticals, Inc.
2 April 2014
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex(TM)
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex(TM)
17 March 2014
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals’ Zerenex(TM) Data Selected for Poster Presentation at the AMCP’s 26th Annual Meeting and Expo
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals’ Zerenex(TM) Data Selected for Poster Presentation at the AMCP’s 26th Annual Meeting and Expo
10 March 2014
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines Agency
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines Agency
18 February 2014
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing
10 February 2014
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Appoints Greg Madison as Chief Operating Officer
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Appoints Greg Madison as Chief Operating Officer
21 January 2014
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access
18 December 2013
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Issuance of U.S. Patent for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Issuance of U.S. Patent for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate
8 November 2013
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis
5 November 2013
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus and
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus and